COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies
ConclusionsIn this global survey of> 1100 EP professionals regarding hospitalized COVID-19 patients, a variety of arrhythmic manifestations were observed, ranging from benign to potentially life-threatening. Observed adverse events related to use of HCQ + AZM included prolonged QTc requiring drug discontinuation as well as Torsade d e Pointes. Large prospective studies to better define arrhythmic manifestations as well as the safety of treatment strategies in COVID-19 patients are warranted.
Source: Journal of Interventional Cardiac Electrophysiology - Category: Cardiology Source Type: research
More News: Amiodarone | Arrhythmia | Atrial Fibrillation | Azithromycin | Cardiac Arrhythmia | Cardiology | COVID-19 | Heart | Hydroxychloroquine | Study | Ventricular Arrhythmia | Ventricular Tachycardia | Zithromax